Search

Your search keyword '"Simeprevir"' showing total 16 results
Start Over Descriptor "Simeprevir" Publication Type Magazines
16 results on '"Simeprevir"'

1. 2 CARDIOVASCULAR DISEASE

Subjects
Merck & Company Inc., Bayer AG, Pfizer Inc., Novartis AG, AstraZeneca PLC, Calcium channels, Riociguat, Hypertension -- Care and treatment -- Risk factors, Elbasvir, Ivabradine, Antilipemic agents, Amlodipine, Temsirolimus, Letermovir, Vardenafil, Angina pectoris -- Care and treatment -- Risk factors, Protease inhibitors, Pharmaceutical industry, Fosamprenavir, Everolimus, Lopinavir, Atorvastatin, Darunavir, Simeprevir, Coronary heart disease, Grazoprevir, Diseases, Heart diseases, Cardiovascular diseases, Health, Maxzide (Medication), Norvasc (Medication)
Abstract

2A Angina >CADUET Pfizer Rx Calcium channel blocker (CCB) + HMG-CoA reductase inhibitor. Amlodipine (as besylate), atorvastatin (as calcium); 2.5mg/10mg, 2.5mg/20mg, 2.5mg/40mg, 5mg/10mg, 5mg/20mg, 5mg/40mg, 5mg/80mg, 10mg/10mg, 10mg/20mg, 10mg/40mg, 10mg/80mg; [...]

Published
2020

2. 2 CARDIOVAS CULAR DISEASE

Subjects
Merck & Company Inc., Bayer AG, Pfizer Inc., Novartis AG, AstraZeneca PLC, Calcium channels, Riociguat, Hypertension -- Care and treatment -- Risk factors, Elbasvir, Ivabradine, Antilipemic agents, Temsirolimus, Vardenafil, Angina pectoris -- Care and treatment -- Risk factors, Protease inhibitors, Pharmaceutical industry, Fosamprenavir, Everolimus, Lopinavir, Atorvastatin, Darunavir, Simeprevir, Coronary heart disease, Grazoprevir, Amlodipine, Diseases, Boceprevir, Heart diseases, Cardiovascular diseases, Health, Maxzide (Medication), Norvasc (Medication)
Abstract

>CADUET Pfizer Rx Calcium channel blocker (CCB) + HMG-CoA reductase inhibitor. Amiodipine (as besylate), atorvastatin (as calcium); 2.5mg/10mg, 2.5mg/20mg, 2.5mg/40mg, 5mg/10mg, 5mg/20mg, 5mg/40mg, 5mg/80mg, 10mg/10mg, 10mg/20mg, 10mg/40mg, 10mg/80mg; tabs. Indications: [...]

Published
2020

3. 2 CARDIOVASCULAR DISEASE

Subjects
Merck & Company Inc., Bayer AG, Pfizer Inc., Novartis AG, AstraZeneca PLC, Calcium channels, Riociguat, Hypertension -- Care and treatment -- Risk factors, Elbasvir, Ivabradine, Antilipemic agents, Temsirolimus, Thioridazine, Vardenafil, Angina pectoris -- Care and treatment -- Risk factors, Protease inhibitors, Pharmaceutical industry, Fosamprenavir, Everolimus, Lopinavir, Atorvastatin, Darunavir, Simeprevir, Coronary heart disease, Grazoprevir, Amlodipine, Boceprevir, Heart diseases, Cardiovascular diseases, Health, Maxzide (Medication), Norvasc (Medication)
Abstract

2A Angina >CADUET Pfizer Rx Calcium channel blocker (CCB) + HMG-CoA reductase inhibitor. Amlodipine (as besylate), atorvastatin (as calcium); 2.5mg/10mg, 2.5mg/20mg, 2.5mg/40mg, 5mg/10mg, 5mg/20mg, 5mg/40mg, 5mg/80mg, 10mg/10mg, 10mg/20mg, 10mg/40mg, 10mg/80mg; [...]

Published
2019

4. 2 CARDIOVASCULAR DISEASE

Subjects
Merck & Company Inc., Bayer AG, Pfizer Inc., Novartis AG, AstraZeneca PLC, Calcium channels, Riociguat, Hypertension -- Care and treatment -- Risk factors, Elbasvir, Ivabradine, Antilipemic agents, Temsirolimus, Thioridazine, Vardenafil, Angina pectoris -- Care and treatment -- Risk factors, Protease inhibitors, Pharmaceutical industry, Fosamprenavir, Everolimus, Lopinavir, Atorvastatin, Darunavir, Simeprevir, Coronary heart disease, Grazoprevir, Amlodipine, Boceprevir, Heart diseases, Cardiovascular diseases, Health, Maxzide (Medication), Norvasc (Medication)
Abstract

2A Angina > CADUET Pfizer Rx Calcium channel blocker (CCB) + HMG-CoA reductase inhibitor. Amlodipine (as besylate), atorvastatin (as calcium); 2.5mg/10mg, 2.5mg/20mg, 2.5mg/40mg, 5mg/10mg, 5mg/20mg, 5mg/40mg, 5mg/80mg, 10mg/10mg, 10mg/20mg, 10mg/40mg, [...]

Published
2019

5. 2 CARDIOVASCULAR DISEASE

Subjects
Merck & Company Inc., Bayer AG, Pfizer Inc., Novartis AG, AstraZeneca PLC, Calcium channels, Riociguat, Hypertension -- Care and treatment -- Risk factors, Elbasvir, Ivabradine, Antilipemic agents, Temsirolimus, Thioridazine, Vardenafil, Angina pectoris -- Care and treatment -- Risk factors, Protease inhibitors, Pharmaceutical industry, Fosamprenavir, Everolimus, Lopinavir, Atorvastatin, Darunavir, Simeprevir, Coronary heart disease, Grazoprevir, Amlodipine, Boceprevir, Heart diseases, Cardiovascular diseases, Health, Maxzide (Medication), Norvasc (Medication)
Abstract

2A Angina >CADUET Pfizer Rx Calcium channel blocker (CCB) + HMG-CoA reductase inhibitor. Amlodipine (as besylate), atorvastatin (as calcium); 2.5mg/10mg, 2.5mg/20mg, 2.5mg/40mg, 5mg/10mg, 5mg/20mg, 5mg/40mg, 5mg/80mg, 10mg/10mg, 10mg/20mg, 10mg/40mg, 10mg/80mg; [...]

Published
2019

6. Texas Liver Institute Researchers Report Research in Hepatitis C Virus (Simeprevir, daclatasvir, and sofosbuvir for hepatitis C virus-infected patients: Long-term follow-up results from the open-label, Phase II IMPACT study)

Subjects
Sofosbuvir, Physical fitness, Daclatasvir, Hepatitis C virus, Simeprevir, Liver, Health
Abstract

2020 JUL 11 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Fresh data on hepatitis C virus are presented in a new report. [...]

Published
2020

7. New Gastroenterology Findings from Institute Oswaldo Cruz Reported [Prevalence of Baseline Ns3 Resistance-associated Substitutions (Rass) On Treatment With Protease Inhibitors In Patients Infected With Hcv Genotype 1]

Subjects
Sofosbuvir, Physical fitness, Daclatasvir, Proteases, Hepatitis C -- Genetic aspects -- Drug therapy, Simeprevir, Obesity, Anopheles, Protease inhibitors, Gene mutation, Editors, Antiviral agents, Health
Abstract

2019 DEC 14 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Current study results on Health and Medicine - Gastroenterology have been published. [...]

Published
2019

8. Findings on RNA Replicase Inhibitors Detailed by Researchers at Federal University of Santa Catarina (The benefits of a public pharmacist service in chronic hepattis C treatment: The real-life results of sofosbuvir-based therapy)

Subjects
Brazil. Federal University of Santa Catarina, Sofosbuvir, Physical fitness, Daclatasvir, Patient compliance, Biochemistry, Hepatitis C virus, Hepatitis C, Simeprevir, RNA, Infection, Editors, Public health movements, Health
Abstract

2019 NOV 23 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators discuss new findings in Drugs and Therapies - RNA Replicase Inhibitors. [...]

Published
2019

9. >Tolsura

Subjects
Lomitapide, Alfuzosin, Ciclesonide, Idelalisib, Daclatasvir, Dienogest, Lurasidone, Solifenacin, Mycoses -- Drug therapy, Dutasteride, Rifabutin, Nisoldipine, Avanafil, Sufentanil, Aprepitant, Rivaroxaban, Apixaban, Darifenacin, Ivacaftor, Cabergoline, Cilostazol, Eletriptan, Simeprevir, Ticagrelor, Vardenafil, Saxagliptin, Bedaquiline, Cinacalcet, Praziquantel, Alfentanil, Itraconazole, Alitretinoin, Tolvaptan, Naloxegol, Fesoterodine, Silodosin, Eliglustat, Ivabradine, Vorapaxar, Anti-HIV agents, Antiarrhythmia agents, Antihypertensive agents, Antineoplastic agents, Histoplasmosis, Dofetilide, Pharmaceutical industry, Respiratory system agents, Antiparasitic agents, Onychomycosis, Phytosterols, Regorafenib, Aliskiren, Fungi, Efavirenz, Cobicistat, Eplerenone, Antifungal agents, Elvitegravir, Aspergillosis, Bosentan, Temsirolimus, Amphotericin B, Pharmacology, Dronedarone, Everolimus, Maraviroc, Blastomycosis, Cell membranes, Plant lipids, Steroids (Organic compounds), Health
Abstract

Company: Mayne Pharma US Rx Pharmacologic class: Azole antifungal Active ingredients: Itraconazole 65mg; caps. Indication: Blastomycosis. Histoplasmosis. Aspergillosis in patients who are intolerant of or refractory to amphotericin B. Limitations [...]

Published
2019

10. Thousands of patients in England to get new hepatitis C drugs.

Author

Kmietowicz Z

Subjects
Anilides, Antiviral Agents therapeutic use, Benzimidazoles, Carbamates, Cyclopropanes, England, Fluorenes, Hepatitis C, Chronic economics, Heterocyclic Compounds, 3-Ring, Humans, Imidazoles, Lactams, Macrocyclic, Macrocyclic Compounds, Proline analogs & derivatives, Pyrrolidines, Simeprevir, Sofosbuvir, Sulfonamides, Uridine Monophosphate analogs & derivatives, Valine analogs & derivatives, Antiviral Agents economics, Hepatitis C, Chronic drug therapy, Public Health economics
Published
2015
Full Text
View/download PDF

11. [New combination therapy increases chances of recovery].

Author

Jäger-Becker D

Subjects
Clinical Trials, Phase II as Topic, Drug Therapy, Combination, Humans, Liver Cirrhosis drug therapy, Simeprevir, Sofosbuvir, Uridine Monophosphate therapeutic use, Antiviral Agents therapeutic use, Hepatitis C, Chronic drug therapy, Heterocyclic Compounds, 3-Ring therapeutic use, Ribavirin therapeutic use, Sulfonamides therapeutic use, Uridine Monophosphate analogs & derivatives
Published
2015
Full Text
View/download PDF

12. [A new era in therapy of chronic hepatitis C].

Author

Füessl HS

Subjects
Cohort Studies, Drug Administration Schedule, Drug Therapy, Combination, Humans, Randomized Controlled Trials as Topic, Simeprevir, Sofosbuvir, Uridine Monophosphate therapeutic use, Antiviral Agents therapeutic use, Hepatitis C, Chronic drug therapy, Heterocyclic Compounds, 3-Ring therapeutic use, Ribavirin therapeutic use, Sulfonamides therapeutic use, Uridine Monophosphate analogs & derivatives
Published
2015
Full Text
View/download PDF

13. [Chronic hepatitis C. Interferon free therapy also in patients with liver cirrhosis].

Subjects
Drug Therapy, Combination, Humans, Randomized Controlled Trials as Topic, Ribavirin therapeutic use, Simeprevir, Sofosbuvir, Uridine Monophosphate analogs & derivatives, Uridine Monophosphate therapeutic use, Antiviral Agents therapeutic use, Hepatitis C, Chronic drug therapy, Heterocyclic Compounds, 3-Ring therapeutic use, Liver Cirrhosis drug therapy, Sulfonamides therapeutic use
Published
2014

14. WHO issues guidelines on HCV amid drug cost controversy.

Author

Slomski A

Subjects
Antiviral Agents therapeutic use, Heterocyclic Compounds, 3-Ring economics, Heterocyclic Compounds, 3-Ring therapeutic use, Humans, Practice Guidelines as Topic, Simeprevir, Sofosbuvir, Sulfonamides economics, Sulfonamides therapeutic use, Uridine Monophosphate analogs & derivatives, Uridine Monophosphate economics, Uridine Monophosphate therapeutic use, World Health Organization, Antiviral Agents economics, Drug Costs, Hepatitis C drug therapy
Published
2014
Full Text
View/download PDF

15. FDA approvals usher in the post-interferon era in HCV.

Author

Sheridan C

Subjects
Drug Approval legislation & jurisprudence, Drug Industry legislation & jurisprudence, Hepacivirus pathogenicity, Hepatitis C virology, Humans, Simeprevir, Sofosbuvir, United States, United States Food and Drug Administration legislation & jurisprudence, Uridine Monophosphate therapeutic use, Hepacivirus drug effects, Hepatitis C drug therapy, Heterocyclic Compounds, 3-Ring therapeutic use, Sulfonamides therapeutic use, Uridine Monophosphate analogs & derivatives
Published
2014
Full Text
View/download PDF

16. Simeprevir approved for hepatitis C virus infection.

Author

Traynor K

Subjects
Drug Therapy, Combination, Hepatitis C genetics, Hepatitis C virology, Hepatitis C, Chronic drug therapy, Humans, RNA, Viral biosynthesis, Simeprevir, Viral Nonstructural Proteins antagonists & inhibitors, Viral Nonstructural Proteins genetics, Antiviral Agents therapeutic use, Hepatitis C drug therapy, Heterocyclic Compounds, 3-Ring therapeutic use, Sulfonamides therapeutic use
Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results